Antifungals: what we have, what we will have, what we want

It is estimated that 300 million people have some fungal infection, and 1.5 million die annually because of it, similar to the mortality from tuberculosis and three times more than malaria. These numbers may be higher since mycoses are not mandatory reporting. With the lessons learned during the SARS-CoV-19 pandemic, the 2022 outbreak of Monkeypox, the resistance to antibacterial, and the recognition by the WHO that mycoses receive very little attention and resources, added to the fact that available antifungals have significant adverse effects, poor oral bioavailability and growing resistance, it is imperative to develop new antifungals with better pharmacokinetics and pharmacodynamic characteristics, a broad spectrum at affordable costs and worldwide supply. It is what we want. A huge challenge.